Multivariate analysis
| Outcome . | RR . | 95% CI . | P* . |
|---|---|---|---|
| OS | |||
| Age | |||
| 40-49 | 1 | .19 | |
| 50-59 | 0.77 | 0.52-1.14 | |
| ≥ 60 | 1.07 | 0.70-1.65 | |
| Disease status | |||
| CP1 | 1 | < .0001 | |
| AP/CP2+ | 1.84 | 1.29-2.64 | |
| BP | 4.71 | 2.7-8.20 | |
| Pre-HCT imatinib | |||
| Yes | 1 | .012 | |
| No | 1.66 | 1.17-2.34 | |
| TRM | |||
| Age | |||
| 40-49 | 1 | .51 | |
| 50-59 | 0.74 | 0.43-1.25 | |
| 60+ | 0.78 | 0.37-1.64 | |
| Disease status | |||
| CP1 | 1 | .0005 | |
| AP/CP2+ | 1.63 | 0.97-2.76 | |
| BP | 5.23 | 2.26-12.07 | |
| HLA match | |||
| HLA sib | 1 | .036 | |
| URD well matched | 0.87 | 0.47-1.59 | |
| URD partially matched | 1.62 | 0.85-3.08 | |
| URD mismatch | 2.98 | 1.27-7.02 | |
| aGVHD | |||
| HLA match | |||
| Sibling | 1 | .014 | |
| URD well matched | 1.033 | 0.63-1.70 | |
| URD partially matched | 1.92 | 1.09-3.39 | |
| URD mismatched | 2.36 | 1.06-5.27 | |
| cGVHD | |||
| GVHD prophy | |||
| CSA ± MTX ± other | 1 | .002 | |
| Tacrolimus ± MTX ± other | 0.60 | 0.36-0.98 | |
| T-cell depletion | 0.48 | 0.32-0.72 | |
| Conditioning | |||
| NMA | 1 | .013 | |
| RIC | 1.8 | 1.13-2.9 | |
| Imatinib | |||
| Yes | 1 | .032 | |
| No | 0.57 | 0.36-0.91 | |
| Relapse | |||
| Age | |||
| 40-49 | 1 | .0003 | |
| 50-59 | 1.06 | 0.69-1.64 | |
| ≥ 60 | 2.28 | 1.44-3.61 | |
| Disease status | |||
| CP1 | 1 | .012 | |
| AP/CP2+ | 1.34 | 0.92-1.94 | |
| BP | 2.82 | 1.40-5.68 | |
| Conditioning intensity | |||
| NMA | 1 | < .0001 | |
| RIC | 0.32 | 0.22-0.47 | |
| Sex | |||
| Male | 1 | .0032 | |
| Female | 0.57 | 0.40-0.83 | |
| DFS | |||
| Age | |||
| 40-49 | 1 | .011 | |
| 50-59 | 0.91 | 0.65-1.27 | |
| ≥ 60 | 1.55 | 1.06-2.26 | |
| Disease status | |||
| CP1 | 1 | < .0001 | |
| AP/CP2+ | 1.42 | 1.05-1.92 | |
| BP | 3.52 | 2.09-5.93 | |
| Conditioning intensity | |||
| NMA | 1 | < .0001 | |
| RIC | 0.45 | 0.33-0.61 | |
| Sex | |||
| Male | 1 | .0027 | |
| Female | 0.64 | 0.48-0.86 |
| Outcome . | RR . | 95% CI . | P* . |
|---|---|---|---|
| OS | |||
| Age | |||
| 40-49 | 1 | .19 | |
| 50-59 | 0.77 | 0.52-1.14 | |
| ≥ 60 | 1.07 | 0.70-1.65 | |
| Disease status | |||
| CP1 | 1 | < .0001 | |
| AP/CP2+ | 1.84 | 1.29-2.64 | |
| BP | 4.71 | 2.7-8.20 | |
| Pre-HCT imatinib | |||
| Yes | 1 | .012 | |
| No | 1.66 | 1.17-2.34 | |
| TRM | |||
| Age | |||
| 40-49 | 1 | .51 | |
| 50-59 | 0.74 | 0.43-1.25 | |
| 60+ | 0.78 | 0.37-1.64 | |
| Disease status | |||
| CP1 | 1 | .0005 | |
| AP/CP2+ | 1.63 | 0.97-2.76 | |
| BP | 5.23 | 2.26-12.07 | |
| HLA match | |||
| HLA sib | 1 | .036 | |
| URD well matched | 0.87 | 0.47-1.59 | |
| URD partially matched | 1.62 | 0.85-3.08 | |
| URD mismatch | 2.98 | 1.27-7.02 | |
| aGVHD | |||
| HLA match | |||
| Sibling | 1 | .014 | |
| URD well matched | 1.033 | 0.63-1.70 | |
| URD partially matched | 1.92 | 1.09-3.39 | |
| URD mismatched | 2.36 | 1.06-5.27 | |
| cGVHD | |||
| GVHD prophy | |||
| CSA ± MTX ± other | 1 | .002 | |
| Tacrolimus ± MTX ± other | 0.60 | 0.36-0.98 | |
| T-cell depletion | 0.48 | 0.32-0.72 | |
| Conditioning | |||
| NMA | 1 | .013 | |
| RIC | 1.8 | 1.13-2.9 | |
| Imatinib | |||
| Yes | 1 | .032 | |
| No | 0.57 | 0.36-0.91 | |
| Relapse | |||
| Age | |||
| 40-49 | 1 | .0003 | |
| 50-59 | 1.06 | 0.69-1.64 | |
| ≥ 60 | 2.28 | 1.44-3.61 | |
| Disease status | |||
| CP1 | 1 | .012 | |
| AP/CP2+ | 1.34 | 0.92-1.94 | |
| BP | 2.82 | 1.40-5.68 | |
| Conditioning intensity | |||
| NMA | 1 | < .0001 | |
| RIC | 0.32 | 0.22-0.47 | |
| Sex | |||
| Male | 1 | .0032 | |
| Female | 0.57 | 0.40-0.83 | |
| DFS | |||
| Age | |||
| 40-49 | 1 | .011 | |
| 50-59 | 0.91 | 0.65-1.27 | |
| ≥ 60 | 1.55 | 1.06-2.26 | |
| Disease status | |||
| CP1 | 1 | < .0001 | |
| AP/CP2+ | 1.42 | 1.05-1.92 | |
| BP | 3.52 | 2.09-5.93 | |
| Conditioning intensity | |||
| NMA | 1 | < .0001 | |
| RIC | 0.45 | 0.33-0.61 | |
| Sex | |||
| Male | 1 | .0027 | |
| Female | 0.64 | 0.48-0.86 |
Overall P value.